Nantahala Capital Management, LLC

Related company / holding

Talphera, Inc.Evoke Pharma IncFTD Companies, Inc.Sucampo Pharmaceuticals, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 1 saleFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (8 ops.)

€1.5M

Latest filing published 19 Dec 2025 for Evoke Pharma Inc, €1.4M.

Filing timeline

BuySale

Nantahala Capital Management, LLC

Insider track record

Disclosed buys

Disclosed sells

Signal history

Nantahala Capital Management, LLC: trading record in brief

Nantahala Capital Management, LLC is a declared insider at 4 companies; the most frequent names are Sucampo Pharmaceuticals, Inc., Evoke Pharma Inc and FTD Companies, Inc. Over a trading history stretching from 23 April 2012 to 17 December 2025, the count stands at 10 filings.

Sales make up the whole of the open-market record (8 sales, €1.5M). No amount is published for 2 filings, which the totals therefore leave out. Besides market trades, the filings include 1 share grant. Since January 2025: no purchases and 1 sale on the market.

The record was last updated on 19 December 2025 with a transaction (€1.4M) in Evoke Pharma Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.